Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-Label Study of Rinzimetostat (ORIC-944) in Combination with Darolutamide Compared with ARPI or Docetaxel in Patients with Metastatic Castration Resistant Prostate Cancer Previously Treated with Abiraterone Acetate (Himalayas-1)'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
National Cancer Centre
Trial Status: NA
Principal Investigator(s):
Dr Ang Jia Ming Daniel
Published by HT Digital Content Services with permission from Health Daily Digest....